Anabolic Therapy of Osteoporosis in Women and in Men

Principles of Gender-Specific Medicine

Volumn 2, Issue , 2004, Pages 995-1009

  Rubin, Mishaela R ^a   Bilezikian, John P ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882479482     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012440905-7/50366-2     Document Type: Chapter

References (185)

1. Consensus Development Conference on Osteoporosis. Am J Med 1993, 95:1S-78S.
2. Orwoll ES, Klein RF Osteoporosis in men. Endocr Rev 1995, 16:87-116.
3. National Osteoporosis Foundation Advocacy-The State of Osteoporosis and Low Bone Mass in the US 2002, National Osteoporosis Foundation, Washington, DC.
4. Riggs BL, Khosla S, Melton LJ A unitary model for involutional osteoporosis: Estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men [see comments]. J Bone Miner Res 1998, 13:763-773.
5. Falahati-Nini A, Riggs BL, Atkinson EJ, et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 2000, 106:1553-1560.
6. Kanis JA, Johnell O, Oden A, et al. Long-term risk of osteoporotic fracture in Malm inverted question mark. Osteoporos Int 2000, 11:669-674.
7. Turner RT, Wakley GK, Hannon KS Differential effects of androgens on cortical bone histomorphometry in gonadectomized male and female rats. J Orthop Res 1990, 8:612-667.
8. Seeman E Clinical review 137: Sexual dimorphism in skeletal size, density, and strength. J Clin Endocrinol Metab 2001, 86:4576-4584.
9. Parfitt AM Quantum concept of bone remodeling and turnover: Implications for the pathogenesis of osteoporosis. Calcif Tissue Int 1979, 28:1-5.
10. Meier DE, Orwoll ES, Jones JM Marked disparity between trabecular and cortical bone loss with age in healthy men. Measurement by vertebral computed tomography and radial photon absorptiometry. Ann Intern Med 1984, 101:605-612.
11. Ruff CB, Hayes WC Sex differences in age-related remodeling of the femur and tibia. J Orthop Res 1988, 6:886-896.
12. Duan Y, Turner CH, Kim BT, Seeman E Sexual dimorphism in vertebral fragility is more theresult of gender differences in age-related bone gain than bone loss. J Bone Miner Res 2001, 16:2267-2275.
13. Melton LJ, Atkinson EJ, O'Fallon WM, et al. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993, 8:1227-1233.
14. Faulkner KG Bone matters: Are density increases necessary to reduce fracture risk?. J Bone Miner Res 2000, 15:183-187.
15. Marshall D, Johnell O, Wedel H Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996, 312:1254-1259.
16. Cheng XG, Nicholson PH, Boonen S, et al. Prediction of vertebral strength in vitro by spinal bone densitometry and calcaneal ultrasound. J Bone Miner Res 1997, 12:1721-1728.
17. Hui SL, Slemenda CW, Johnston CC Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 1988, 81:1804-1809.
18. Orwoll E Assessing bone density in men. J Bone Miner Res 2000, 15:1867-1870.
19. Cooley H, Jones G A population-based study of fracture incidence in southern Tasmania: Lifetime fracture risk and evidence for geographic variations within the same country. Osteoporos Int 2001, 12:124-130.
20. Effects of hormone therapy on bone mineral density: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI [see comments]. JAMA 1996, 276:1389-1396.
21. Chesnut CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000, 109:267-276.
22. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282:637-645.
23. Lindsay R, Cosman F The Pharmacology of Estrogens in Osteoporosis. Principles of Bone Biology 1996, 1063-1068. Academic Press, Sand Diego, CA. J.P. Bilezikian, L.G. Raisz, G.A. Rodan (Eds.).
24. Fleisch H Bisphosphonates: Mechanisms of Action and Clinical Use. Principles of Bone Biology 1996, 1037-1052. Academic Press, Sand Diego, CA. J.P. Bilezikian, L.G. Raisz, G.A. Rodan (Eds.).
25. Azria M, Avioli L Calcitonin. Principles of Bone Biology 1996, 1083-1098. Academic Press, San Diego, CA. J.P. Bilezikian, L.G. Raisz, G.A. Rodan (Eds.).
26. Fogelman I, Ribot C, Smith R, et al. Risedronate reverses bone loss in postmenopausal women with low bone mass: Results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab 2000, 85:1895-1900.
27. Kurland ES, Rosen CJ, Cosman F, et al. Insulin-like growth factor-I in men with idiopathic osteoporosis [see comments]. J Clin Endocrinol Metab 1997, 82:2799-2805.
28. Greenspan SL, Parker RA, Ferguson L, et al. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: A randomized clinical trial. J Bone Miner Res 1998, 13:1431-1438.
29. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group [see comments]. N Engl J Med 1995, 333:1437-1443.
30. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995, 333:1437-1443.
31. Wasnich RD, Miller PD Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000, 85:231-236.
32. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002, 112:281-289.
33. Miller PD, Bonnick SL, Rosen CJ Consensus of an international panel on the clinical utility of bone mass measurements in the detection of low bone mass in the adult population. Calcif Tissue Int 1996, 58:207-214.
34. Marcus R, Wong M, Heath H, Stock JL Antiresorptive treatment of postmenopausal osteoporosis: Comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 2002, 23:16-37.
35. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group [see comments]. Lancet 1996, 348:1535-1541.
36. Seeman E, McLung M, Zippel H, et al. Rapid and sustained effect of risedronate in reducing hip fracture risk. J Bone Miner Metab 2000, 15(Suppl 1):S149.
37. Watts N, Adami S, Chesnut CH Risedronate reduces the risk of clinical vertebral fractures in just 6 months. J Bone Miner Metab 2001, 16(S1):S407.
38. Parfitt AM Use of bisphosphonates in the prevention of bone loss and fractures. Am J Med 1991, 91(5B):42S-46S.
39. Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS Prospective Study. J Bone Miner Res 1996, 11:1531-1538.
40. Melton LJ, Khosla S, Atkinson EJ, et al. Relationship of bone turnover to bone density and fractures. J Bone Miner Res 1997, 12:1083-1091.
41. Riggs BL, Melton LJ Bone turnover matters: The raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 2002, 17:11-14.
42. Ito M, Amizuka N, Nakajima T, Ozawa H Ultrastructural and cytochemical studies on cell death of osteoclasts induced by bisphosphonate treatment. Bone 1999, 25:447-452.
43. Hochberg MC, Greenspan S, Wasnich RD, et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002, 87:1586-1592.
44. Dempster DW, Cosman F, Kurland ES, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 2001, 16:1846-1853.
45. Parfitt AM, Mathews CH, Villanueva AR, et al. Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss. J Clin Invest 1983, 72:1396-1409.
46. Silva MJ, Gibson LJ Modeling the mechanical behavior of vertebral trabecular bone: Effects of age-related changes in microstructure. Bone 1997, 21:191-199.
47. Mosekilde L Age-related changes in vertebral trabecular bone architecture-Assessed by a new method. Bone 1988, 9:247-250.
48. Borah B, Dufresne TE, Chmielewski PA, et al. Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J Bone Miner Res 2002, 17:1139-1147.
49. Bell GH, Dunbar O, Beck JS, Gibb A Variations in strength of vertebrae with age and their relation to osteoporosis. Calcif Tissue Res 1967, 1:75-86.
50. Meunier PJ, Boivin G Bone mineral density reflects bone mass but also the degree of mineralization of bone: Therapeutic implications. Bone 1997, 21:373-377.
51. Boivin GY, Chavassieux PM, Santora AC, et al. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000, 27:687-694.
52. Boivin G, Meunier PJ Changes in bone remodeling rate influence the degree of mineralization of bone. Connect Tissue Res 2002, 43:535-537.
53. Hernandez CJ, Beaupre GS, Keller TS, Carter DR The influence of bone volume fraction and ash fraction on bone strength and modulus. Bone 2001, 29:74-78.
54. Roschger P, Grabner BM, Messer P, et al. Influence of intermittent PTH treatment on mineral distribution in the human ilium: A paired biopsy study before and after treatment. J Bone Miner Res 2001, 16(Suppl 1):S179.
55. Noble BS, Reeve J Osteocyte function, osteocyte death and bone fracture resistance. Mol Cell Endocrinol 2000, 159:7-13.
56. Plotkin LI, Weinstein RS, Parfitt AM, et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999, 104:1363-1374.
57. Albright F, Aub JC, Bauer W Hyperparathyroidism: A common and polymorphic condition as illustrated by seventeen proven cases from one clinic. JAMA 1934, 102:1276-1287.
58. Albright F, Reifenstein EC The Parathyroid Glands and Metabolic Bone Disease 1948, Williams & Wilkins, Baltimore.
59. Juppner H, Kronenberg HM PTH: Mechanism of Action. Primer on Metabolic Bone Diseases 1996, 117-124. ASBMR, Washington, DC. M. Favus (Ed.).
60. Morley P, Whitfield JF, Willick GE Anabolic effects of PTH on bone. Trends Endocrinol Metab 1997, 8:225-231.
61. Abou-Samra AB, Jueppner H, Westerberg D, et al. Parathyroid hormone causes translocation of protein kinase-C from cytosol to membranes in rat osteosarcoma cells. Endocrinology 1989, 124:1107-1113.
62. Fraher LJ, Avram R, Watson PH, et al. Comparison of the biochemical responses to human parathyroid hormone-(1-3)NH2 and hPTH-(1-34) in healthy humans. J Clin Endocrinol Metab 1999, 84:2739-2743.
63. Canalis E, Centrella M, Burch W, McCarthy TL Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. J Clin Invest 1989, 83:60-65.
64. Hock JM, Gera I, Fonseca J, Raisz LG Human parathyroid hormone-(1-34) increases bone mass in ovariectomized and orchidectomized rats. Endocrinology 1988, 122:2899-2904.
65. Linkhart TA, Mohan S Parathyroid hormone stimulates release of insulin-like growth factor-I (IGF-I) and IGF-II from neonatal mouse calvaria in organ culture. Endocrinology 1989, 125:1484-1491.
66. Watson PH, Lazowski DA, Han V, et al. PTH restores bone mass and enhances osteoblast IGF-1 gene expression in ovariectomized rats. Bone 1995, 16:1-9.
67. Ma YL, Cain RL, Halladay DL, et al. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 2001, 142:4047-4054.
68. Ilda-Klein A, Zhou H, Lu SS, et al. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. J Bone Miner Res 2002, 17:808-816.
69. Jilka RL, Weinstein RS, Bellido T, et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999, 104:439-446.
70. Baumann AP, Grasser W, Petras S, et al. Inhibition of osteoclast formation by statins. J Bone Miner Res 2001, 16(Suppl 1):M309.
71. Locklin RM, Khosla S, Riggs BL Mechanisms of biphasic anabolic and catabolic effects of parathyroid hormone (PTH) on bone cells. Bone Suppl 2001, 28:s80.
72. Baumann BD, Wronski TJ Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats. Bone 1995, 16:247-253.
73. Cheng PT, Chan C, Muller K Cyclical treatment of osteopenic ovariectomized adult rats with PTH(1-34) and pamidronate. J Bone Miner Res 1995, 10:119-126.
74. Burr DB, Hirano T, Turner CH, et al. Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 2001, 16:157-165.
75. Kneissel M, Boyde A, Gasser JA Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1-34). Bone 2001, 28:237-250.
76. Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002, 30:312-321.
77. Hurley MM, Okada Y, Sobue T, et al. The anabolic effect of parathyroid hormone is impaired in bones of Fgf2 null mice. J Bone Miner Metab 2002, 17(Suppl 1):1061.
78. Li J, Duncan RL, Burr DB, Turner CH L-type calcium channels mediate mechanically induced bone formation in vivo. J Bone Miner Res 2002, 17:1795-1800.
79. Lane N, Yao W, Arnaud CD The association of serum RANKL and OPG levels with other biochemical markers of bone turnover in glucocorticoid induced osteoporosis patients treated with hPTH (1-34). J Bone Miner Res 2002, 17(suppl 1):F366.
80. Jiang Y, Zhao JJ, Mitlak BH, et al. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003, 18(11):1932-1941.
81. Cosman F, Lindsay R Is parathyroid hormone a therapeutic option for osteoporosis? A review of the clinical evidence. Calcif Tissue Int. 1998, 62:475-480.
82. Rittmaster RS, Bolognese M, Ettinger MP, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate [see comments]. J Clin Endocrinol Metab 2000, 85:2129-2134.
83. Chesnut CH, Rose CJ Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J Bone Miner Res 2001, 16:2163-2172.
84. Cosman F, Nieves J, Woelfert L, et al. Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001, 16:925-931.
85. Gori F, Hofbauer LC, Conover CA, Khosla S Effects of androgens on the insulin-like growth factor system in an androgen-responsive human osteoblastic cell line. Endocrinology 1999, 140:5579-5586.
86. Neer R, Hayes A, Rao A, Finkelstein J Effects of parathyroid hormone, alendronate, or both on bone density in osteoporotic postmenopausal women. J Bone Miner Metab 2002, 17(Suppl 1):1039.
87. Rubin MR, Bilezikian JP Clinical review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: A re-examination of the evidence. J Clin Endocrinol Metab 2002, 87:4033-4041.
88. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
89. Kurland ES, Cosman F, McMahon D, et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000, 85:3069-3076.
90. Kurland E, Cosman F, McMahon DJ, et al. Parathyroid hormone (PTH 1-34) increases cancellous bone mass markedly in men with idiopathic osteoporosis (abstract). Bone 1998, 23(Suppl 5):S158.
91. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide (human parathyroid hormone [1-34]) therapy on bone density in men with osteoporosis. J Bone Miner Res 2003, 18(1):9-17.
92. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
93. Finkelstein J, Hayes A, Rao A, Neer R Effects of parathyroid hormone, alendronate, or both on bone density in osteoporotic men. J Bone Miner Metab 2002, 17(Suppl 1):1007.
94. Dempster D, Zhou H, Cosman F, et al. PTH treatment directly stimulates bone formation in cancellous and cortical bone in humans. J Bone Miner Res 2001, 16(suppl 1):1171.
95. Kurland ES, Cosman F, Rosen CJ, et al. Parathyroid hormone (PTH 1-34) as a treatment for idiopathic osteoprosis in men: Changes in bone mineral density, bone markers and optimal duration of therapy. J Bone Miner Res 2000, 15(suppl 1):F435.
96. Eriksen EF Primary hyperparathyroidism: Lessons from bone histomorphometry. J Bone Miner Res 2002, 17(Suppl 2):N95-N97.
97. Nishida S, Yamaguchi A, Tanizawa T, et al. Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone 1994, 15:717-723.
98. Uchida A, Kikuchi T, Shimomura Y. Osteogenic capacity of culture human periosteal cells. Cata Orthop Scand 1988, 59:29-33.
99. Parfitt AM Parathyroid hormone and periosteal bone expansion. J Bone Miner Res 2002, 17:1741-1743.
100. Zanchetta JR, Bogado CE, Ferretti JL, et al. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003, 18:539-543.
101. Hirano T, Burr DB, Turner CH, et al. Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34). LY33334, on remodeling and mechanical properties of cortical bone in rabbits. J Bone Miner Res 1999, 14:536-545.
102. Ejersted C, Andreassen T, Oxlund H, et al. Human parathyroid hormone (1-34) and (1-84) increase the mechanical strength and thickess of cortical bone in rats. J Bone Miner Res 1993, 8:1087-1101.
103. Mosekilde L Sex differences in age-related changes in vertebral body size, density and biomechanical competence in normal individuals. Bone 1990, 11:67-73.
104. Hyldstrup L, Jorgensen JT, Gaich GA Assessment of effects of LY33334 [recombinant human parathyroid hormone (1-34)] on cortical bone using digital X-ray radiogrametry. First Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society 2001, SC33S. IBMS, Madrid.
105. Sato M, Westmore M, Clendenon J, et al. Three-dimensional modeling of the effects of parathyroid hormone on bone distribution in lumbar vertebrae of ovariectomized cynomolgus macaques. Osteoporos Int 2000, 11:871-880.
106. Mashiba T, Burr DB, Turner CH, et al. Effects of human parathyroid hormone (1-34), LY33334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits. Bone 2001, 28:538-547.
107. Fermor B, Skerry TM PTH/PTHrP receptor expression on osteoblasts and osteocytes but not resorbing bone surfaces in growing rats. J Bone Miner Res 1995, 10:1935-1943.
108. van der Plas A, Aarden EM, Feijen JM, et al. Characteristics and properties of osteocytes in culture. J Bone Miner Res 1994, 9:1697-1704.
109. Black DM, Rosen CJ, Greenspan SL, et al. PTH and biosphosphonates in the treatment of osteoporosis: Design of the PTH and alendronate (PaTH) trial (abstract). ASMMR 23rd Annual Meeting 2001.
110. Black DM, Rosen CJ Parsimony with PTH: Is a single weekly injection of PTH Superior to a larger cumulative dose given daily. J Bone Miner Res 2002, 17(Suppl 1):SA367.
111. Misof BM, Roschger P, Cosman F, et al. Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: A paired study before after treatment. J Clin Endocrinol Metab 2003, 88:1150-1166.
112. Dempster DW, Parisien M, Silverberg SJ et al. On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperpathyridsm. J Clin Endocrinol Metab. 84:1562-1566.
113. Linsday R, Scheele WH, Clancy AD et al. Reduction in nonvertebral fragility fractures and increase in spinal bone density is maintained 31 months after discontinuation of recombinant human parathyroid hormone (1-34) in post-menopausal women with osteoporosis. Eight-fourth Annual Meeting of the Endocrine Society, Bethesda, MD: Endocrine Society, pp. OR35-36.
114. Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997, 350:550-555.
115. Lane NE, Sanchez S, Modin GW, et al. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: Results of a randomized controlled clinical trial. J Bone Miner Res 2000, 15:944-951.
116. Christiansen P, Steiniche T, Mosekilde L, et al. Primary hyperparthyroidism: Changes in trabecular bone remodeling following surgical treatment-Evaluated by histomorphometric methods. Bone 1990, 11:75-79.
117. Kurland ES, Heller SL, Cosman F, et al. The post-PTH experience in men with idiopathic osteoporosis: Bisphosphonates vs. non-pharmacologic therapy. J Bone Miner Res 2001, 16(suppl 1).
118. Rhee Y, Kim S, Nangung R, et al. Maintenance of increased bone mass after rhPTH (1-84) with zoledranate treatment in ovariectomized rats. J Bone Miner Metab 2002, 17(Suppl 1):SA 337.
119. Tashjian AH, Chabner BA Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res. 2002, 17:1151-1161.
120. Betancourt M, Wirfel KL, Raymond AK, et al. Osteosarcoma of bone in a patient with primary hyperparathyroidism: A case report. J Bone Miner Res 2003, 18:163-166.
121. Palmer M, Adami HO, Krusemo UB, Ljunghall S. Increased risk of malignant diseases after surgery for primary hyperparathyroidism. A nationwide cohort study. Am J Epidemiol. 1988, 127:1031-1040.
122. Eli Lilly. (2002). FORTEO (teriparaide [rDNA origin] injection. p. 1. package insert.
123. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004, 350(5):459-468.
124. Kleerekoper M, Peterson EL, Nelson DA, et al. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporos Int 1991, 1:155-161.
125. Pak CY, Sakhace K, Zerwekh JE, et al. Safe and effective treatment of osteoporosis with intermittent slow release sodium fluoride: Augmentation of vertebral bone mass and inhibition of fractures. J Clin Endocrinol Metab 1989, 68:150-159.
126. Pak CY, Sakhaee K, Adams-Huet B, et al. Treatment of postmento pausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Intern Med 1995, 123:401-408.
127. Pak CY, Zerwekh JE, Antich PP, et al. Slow-release sodium fluoride in osteoporosis. J Bone Miner Res 1996, 11:561-564.
128. Riggs BL, O'Fallon WM, Lane A, et al. Clinical trial of fluoride therapy in postmenopausal osteoporotic women: Extended observations and additional analysis. J Bone Miner Res 1994, 9:265-275.
129. Ringe JD What is proven about hip fracture and fluoride treatment?. Osteologie 1998, 7:151-156.
130. Peiche P, Zamani O, Kupman W Antiosteoporotic therapy with monofluorophosphate and calcium increases cortical and trabecular bone density. Osteologie 1995, 4:87-98.
131. Fujita T, Inoue T, Morii H, et al. Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: A randomized double-masked prospective study using three dose levels. Osteoporos Int 1999, 9:296-306.
132. Meunier PJ, Sebert JL, Reginster JY, et al. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: The FAVO Study. Osteoporos Int. 1998, 8:4-12.
133. Alexandersen P, Riis BJ, Christiansen C Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: A randomized study. J Clin Endocrinol Metab 1999, 84:3013-3020.
134. Ringe JD, Rovati LC Treatment of osteoporosis in men with fluoride alone or in combination with bipshosphonates. Calcif Tissue Int 2001, 69:252-255.
135. Donahue L, Rosen CJ IGFs and bone. The osteoporosis connection revisited. Proc Soc Exp Biol Med 1998, 219:1-7.
136. Zhao G, Monier-Faugere MC, Langub MC, et al. Targeted over-expression of insulin-like growth factor I to osteoblasts of transgenic mice: Increased trabecular bone volume without increased osteoblast proliferation. Endocrinology 2000, 141:2674-2682.
137. Sugimoto T, Nakaoka D, Nasu M, et al. Effect of recombinant human growth hormone in elderly osteoporotic women. Clin Endocrinol (Oxf) 1999, 51:715-724.
138. Bauer DC, Rosen CJ, Cauley J, Cummings SR Low serum IGF-1 but not IGFBP-3 predicts hip and spine fracture: The study of osteoporotic fracture. J Bone Miner Res 1998, 23:S561.
139. Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990, 323:1-6.
140. Holloway L, Butterfield G, Hintz RL, et al. Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women. J Clin Endocrinol Metab 1994, 79:470-479.
141. Hodsman AB, Farher LJ, Watson PH Parathyroid Hormone. The Aging Skeleton 1999, 563-578. Academic Press, Sand Diegy, CA. C.J. Rosen, J. Glowacki, J.P. Bilezikian (Eds.).
142. Ackert-Bicknell C, Rubin J, Zhu L, et al. IGF-I acts as a coupling factor for bone remodeling by regulating osteoprotegerin and RANK ligand in vitro and osteoprotegerin in vivo. Eight-fourth Annual Meeting of the Endocrine Society 2002, P3-P336. Endocrine Society, Bethesda, MD.
143. Landin-Wilhelmsen K, Nilsson A, Bosaeus I, Bengtsson BA Growth hormone increases bont mineral content in postmenopausal osteoporosis: A randomized placebo-controlled trial. J Bone Miner Res 2003, 18:393-405.
144. Rosen CJ, Wuster C Growth hormone rising: Did we quit too quickly. J Bone Miner Res 2003, 18:406-409.
145. Ghiron LJ, Thompson JL, Holloway L, et al. Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women. J Bone Miner Res 1995, 10:1844-1852.
146. Grinspoon S, Baum H, Lee K, et al. Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa. J Clin Endocrnol Metab 1996, 81:3864-3870.
147. Body JJ, Gaich GA, Scheele WH, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002, 87:4528-4535.
148. Geusens P, Bouillon R, Broos P Musculoskeletal effects of rhIGF-I/IGFBP-3 in hip fracture patients: Results from a double-blind, placebo controlled phase II study. Bone 1998, 23:S157.
149. Johnson AR, Armstrong WD, Singer L The incorporation and removal of large amoungs of strontium by physiologic mechanisms in mineralized tissues. Calcifs Tissues Res 1968, 2:242-252.
150. Marie PJ, Amman P, Boivin G, et al. Mechanism of action and therapeutic potential of strontium in bone. Calcif Tissue Int 2001, 69:121-129.
151. Quarles LD Cation sensing receptors in bone: A novel paradigm for regulating bone remodeling. J Bone Miner Res 1997, 12:1971-1974.
152. Brown EM, MacLeod RJ Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 2001, 81:239-297.
153. Coulombe J, Faure H, Robin B, et al. Activation of the rat and mouse cation-sensing receptor by strontium ranelate and its modulation by extracellular calcium. Osteoporos Int 2002, 13(Suppl 1):S25.
154. Reginster JY, Halkin V, Henrotin Y, Gosset C Treatment of osteoporosis: Role of bone-forming agent. Osteoporos Int 1999, 9(Suppl 2):S91-S96.
155. Meunier PJ, Slosman DO, Delmas PD, et al. Strontium ranelate: Dose-dependent effects in established postmenopausal vertebral osteoporosis-A 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002, 87:2060-2066.
156. Cranney A, Guyatt G, Krolicki N, et al. A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int 2001, 12:140-151.
157. Lees B, Stevenson JC The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17 beta and dydrogesterone. Osteoporos Int 2001, 12:251-258.
158. Meunier PJ, Roux C, Ortolani S, et al. Strontium ranelate reduces the vertebral fracture risk in women with postmenopausal osteoporosis. Osteoporos Int 2002, 13(Suppl 1):045.
159. Chung YS, Lee MD, Lee SK, et al. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 2000, 85:1137-1142.
160. Edwards CJ, Hart DJ, Spector TD Oral statins and increased bonemineral density in postmenopausal women. Lancet 2000, 355:2218-2219.
161. Chan KA, Andrade SE, Boles M, et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 2000, 355:2185-2188.
162. Meier CR, Schlienger RG, Kraenzlin ME, et al. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000, 283:3205-3210.
163. Wang PS, Solomon DH, Mogun H, Avorn J HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000, 283:3211-3216.
164. Pasco JA, Kotowicz MA, Henry MJ, et al. Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med 2000, 162:537-540.
165. Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999, 286:1946-1949.
166. Garrett IR, Gutierrez G, Chen D Statins stimulate bone formation by enhancing eNOS expression. J Bone Miner Res 2001, 16(Suppl 1):1018.
167. Coxon FP, Benford HL, Russell RG, Rogers MJ Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs. Mol Pharmacol 1998, 54:631-638.
168. Sugiyama M, Kodama T, Konishi K, et al. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun 2000, 271:688-692.
169. Maeda T, Matsunuma A, Kawane T, Horiuchi N Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun 2001, 280:874-877.
170. Crawford DT, Qi H, Chidsey-Frink KL, et al. Statin increases cortical bone in young male rats by single, local administration but fails to restore bone in ovariectomized rats by daily systemic administration. J Bone Miner Res 2001, 16(Suppl 1):SA410.
171. Chan MH, Mak TW, Chiu RW, et al. Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesteroterolaemia. J Clin Endocrinol Metab 2001, 86:4556-4559.
172. Braga V, Gatti D, Rossini M, Adami S Association between lipid profile and bone mass in healthy men. J Bone Mine Res 2001, 16(Suppl 1):F307.
173. Solomon DH, Finkelstein JS, Wang PS, Avorn J Statin lipid-lowering drugs and bone density. J Bone Miner Res 2001, 16(Suppl 1):SA399.
174. Reid IR, Hague W, Emberson J, et al. Effect of pravastatin on frequency of fracture in the LIPID study: Secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet 2001, 357:509-512.
175. van Staa TP, Wegman S, de Vries F, et al. Use of statins and risk of fractures. JAMA 2001, 285:1850-1855.
176. LaCroix AZ, Cauley J, Jackson R, et al. Does statin use reduce risk of fracture in postmenopausal women? Results from the Women's Health Initiative Observational Study (WHI-OS). J Bone Miner Res 2000, 15(Suppl 1):1066.
177. Finkelstein JS, Neer RM, Biller BM, et al. Osteopenia in men with a history of delayed puberty. N Engl J Med. 1992, 326:600-604.
178. Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996, 81:4358-4365.
179. Leder BZ, Schoenfeld DA, LeBlanc K, Finkelstein JS Both estradiol and testosterone play fundamental roles in the maintenance of normal bone turnover in men. J Bone Miner Res 2001, 16(suppl 1):1140.
180. Davis SR, McCloud P, Strauss BJ, Burger H Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995, 21:227-236.
181. Watts NB, Notelovitz M, Timmons MC, et al. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol 1995, 85:529-537.
182. Barrett-Connor E, Young R, Notelovitz M, et al. A two-year double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. J Reprod Med 1999, 44:1012-1020.
183. Leone-Bay A, Sato M, Paton D, et al. Oral delivery of biologically active parathyroid hormone. Pharm Res 2001, 18:964-970.
184. Mehta NM, Gilligan JP, Stern B, et al. Biological activity of recombinant PTH analog 7841. J Bone Miner Metab 2002, 17(Suppl 1):SA362.
185. Gowen M, Stroup GB, Dodds RA, et al. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest 2000, 105:1595-1604.